NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Market Report: 16 March

Domestic Benchmarks Decline

The Sensex and Nifty 50 indices faced selling pressure for the third consecutive day on Friday, with the Sensex closing at 74,563.92, down 1,470.50 points, or 1.93%. The Nifty 50 fell by 488.05 points, or 2.06%, finishing at 23,151.10.

Weekly Decline

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

Throughout the week, the BSE benchmark Sensex declined by 4,354.98 points, or 5.51%, while the Nifty 50 decreased by 1,299.35 points, or 5.31%.

GIFT Nifty Live Chart

The GIFT Nifty Live Chart is showing a positive start for the Indian stock market today, with a premium of nearly 140 points from the Nifty futures' previous close of 23,199.30.

Stock Recommendations

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Based on technical analysis and market trends, the following stocks are recommended for purchase:

  • Ajanta Pharma (CMP: ₹3,119.50): Buy above ₹3,125, target ₹3,350 in two months, stop loss ₹2,990.
  • Power Grid Corporation (CMP: ₹303.60): Buy above ₹305, target ₹340 in two months, stop loss ₹280.
  • Timken India (CMP: ₹3,486.50): Buy above ₹3,490, target ₹3,850 in two months, stop loss ₹3,370.
  • Aurobindo Pharma (CMP: ₹1,310): Buy at ₹1,300 to ₹1,325, target ₹1,450 in two to three months, stop loss ₹1,250.

Key Metrics

StockCMPTargetStop Loss
Ajanta Pharma₹3,119.50₹3,350₹2,990
Power Grid Corporation₹303.60₹340₹280
Timken India₹3,486.50₹3,850₹3,370
Aurobindo Pharma₹1,310₹1,450₹1,250

Risk Factors

  • Regulatory compliance
  • Intense market competition
  • Geopolitical issues
  • High capital expenditure
  • Regulatory environment
  • Counterparty weaknesses
  • Industrial slowdowns
  • Geopolitical tensions
  • Lagging revenue growth

Investor Takeaway

Investors should be cautious of the ongoing selling pressure and potential impact on the Indian stock market.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.